Cargando…

Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma

Immune checkpoint inhibitor therapy has shown promising results in patients with unresectable hepatocellular carcinoma. This study aimed to evaluate the effectiveness and safety of sintilimab, a programmed cell death protein-1 (PD-1) blockade, combined with sorafenib and transhepatic arterial chemot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dai, Lei, Cai, Xingchen, Mugaanyi, Joseph, Liu, Yelei, Mao, Shuqi, Lu, Changjiang, Lu, Caide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492645/ https://www.ncbi.nlm.nih.gov/pubmed/34611195 http://dx.doi.org/10.1038/s41598-021-98937-2

Ejemplares similares

Pancreatic adenocarcinoma associated immune-gene signature as a novo risk factor for clinical prognosis prediction in hepatocellular carcinoma
por: Dai, Lei, et al.
Publicado: (2022)

Comprehensive bioinformatic analysis of MMP1 in hepatocellular carcinoma and establishment of relevant prognostic model
por: Dai, Lei, et al.
Publicado: (2022)

A Meta-Analysis and Systematic Review of Normothermic and Hypothermic Machine Perfusion in Liver Transplantation
por: Mugaanyi, Joseph, et al.
Publicado: (2022)

A pan-cancer bioinformatic analysis of the carcinogenic role of SMARCA1 in human carcinomas
por: Dai, Lei, et al.
Publicado: (2022)

Undifferentiated Pancreatic Carcinomas, Clinical Features and Therapeutic Options: What We Know
por: Mugaanyi, Joseph, et al.
Publicado: (2022)

Preoperative nomogram for microvascular invasion prediction based on clinical database in hepatocellular carcinoma
por: Mao, Shuqi, et al.
Publicado: (2021)

Author Correction: Preoperative nomogram for microvascular invasion prediction based on clinical database in hepatocellular carcinoma
por: Mao, Shuqi, et al.
Publicado: (2021)

Extended pancreato-duodenectomy coupled with adjuvant chemotherapy for SMARCB1/INI1 deficient pancreatic carcinoma: A case report and literature review
por: Mugaanyi, Joseph, et al.
Publicado: (2021)

Bile is a reliable and valuable source to study cfDNA in biliary tract cancers
por: Li, Zhanghui, et al.
Publicado: (2022)

Development of nomogram models of inflammatory markers based on clinical database to predict prognosis for hepatocellular carcinoma after surgical resection
por: Mao, Shuqi, et al.
Publicado: (2022)

The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Cao, Fei, et al.
Publicado: (2021)

Risk Factors of Early Liver Metastasis for Pancreatic Ductal Adenocarcinoma after Radical Resection
por: Tong, Jingshu, et al.
Publicado: (2022)

Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report
por: Fu, Lingli, et al.
Publicado: (2021)

A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma
por: Gan, Leijuan, et al.
Publicado: (2023)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Peng, Ye, et al.
Publicado: (2022)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
por: Zhou, Ting, et al.
Publicado: (2022)

Nomogram for the Preoperative Prediction of the Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma
por: Shan, Yuying, et al.
Publicado: (2022)

Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study
por: Li, Dailong, et al.
Publicado: (2022)

Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (MLR)-Based Nomogram Model to Predict Tumor Recurrence of AFP-Negative Hepatocellular Carcinoma
por: Mao, Shuqi, et al.
Publicado: (2021)

Macrotrabecular-massive subtype-based nomogram to predict early recurrence of hepatocellular carcinoma after surgery
por: Yang, Yong, et al.
Publicado: (2023)

Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma
por: Xu, Shuhui, et al.
Publicado: (2023)

Cost‐effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China
por: Xu, Zhe, et al.
Publicado: (2023)

Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients
por: Chen, Jinzhang, et al.
Publicado: (2020)

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Yano, Shigeki, et al.
Publicado: (2023)

Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study
por: Tang, Shi, et al.
Publicado: (2023)

Development and validation of a nomogram to predict liver metastasis for pancreatic ductal adenocarcinoma after radical resection
por: Tong, Jingshu, et al.
Publicado: (2022)

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2021)

Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma
por: Zhang, Menglong, et al.
Publicado: (2022)

Sintilimab: Pneumonitis: case report
Publicado: (2021)

Predictive factors for the benefit of triple‐drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma
por: He, MinKe, et al.
Publicado: (2019)

Retracted: Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma
por: Markers, Disease
Publicado: (2023)

Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
por: Tu, Lingfang, et al.
Publicado: (2021)

Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study
por: Chen, Xiaofeng, et al.
Publicado: (2022)

Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation
por: Wang, Kang, et al.
Publicado: (2023)

Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma
por: Ni, Hong, et al.
Publicado: (2011)

Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors
por: Huang, Nana, et al.
Publicado: (2022)

Recent updates on Sintilimab in solid tumor immunotherapy
por: Liu, Xuhong, et al.
Publicado: (2020)

Sintilimab-Induced Myocarditis in a Patient with Gastric Cancer: A Case Report and Literature Review
por: Liu, Xin, et al.
Publicado: (2023)

Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Long, Jianwu, et al.
Publicado: (2023)

Meta-analysis of the efficacy and safety of sintilimab for treating advanced non-small cell lung cancer
por: Xie, Jiejie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rfhosblfq1snpfjdfrmi590o2t